Prognostic value of circulating markers of neutrophil activation, neutrophil extracellular traps, coagulation and fibrinolysis in patients with terminal cancer

Abstract Predicting survival accurately in patients with advanced cancer is important in guiding interventions and planning future care. Objective tools are therefore needed. Blood biomarkers are appealing due to their rapid measurement and objective nature. Thrombosis is a common complication in ca...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Axel Rosell, Katherina Aguilera, Yohei Hisada, Clare Schmedes, Nigel Mackman, Håkan Wallén, Staffan Lundström, Charlotte Thålin
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/6878c987d3634635982d478f171288b0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6878c987d3634635982d478f171288b0
record_format	dspace
spelling	oai:doaj.org-article:6878c987d3634635982d478f171288b02021-12-02T15:53:45ZPrognostic value of circulating markers of neutrophil activation, neutrophil extracellular traps, coagulation and fibrinolysis in patients with terminal cancer10.1038/s41598-021-84476-32045-2322https://doaj.org/article/6878c987d3634635982d478f171288b02021-03-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-84476-3https://doaj.org/toc/2045-2322Abstract Predicting survival accurately in patients with advanced cancer is important in guiding interventions and planning future care. Objective tools are therefore needed. Blood biomarkers are appealing due to their rapid measurement and objective nature. Thrombosis is a common complication in cancer. Recent data indicate that tumor-induced neutrophil extracellular traps (NETs) are pro-thrombotic. We therefore performed a comprehensive investigation of circulating markers of neutrophil activation, NET formation, coagulation and fibrinolysis in 106 patients with terminal cancer. We found that neutrophil activation and NET markers were prognostic in terminal cancer patients. Interestingly, markers of coagulation and fibrinolysis did not have a prognostic value in this patient group, and there were weak or no correlations between these markers and markers of neutrophil activation and NETs. This suggest that NETs are linked to a poor prognosis through pathways independent of coagulation. Additional studies are needed to determine the utility of circulating neutrophil activation and NET markers, alone or in concert with established clinical parameters, as objective and reliable prognostic tools in advanced cancer.Axel RosellKatherina AguileraYohei HisadaClare SchmedesNigel MackmanHåkan WallénStaffan LundströmCharlotte ThålinNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Axel Rosell Katherina Aguilera Yohei Hisada Clare Schmedes Nigel Mackman Håkan Wallén Staffan Lundström Charlotte Thålin Prognostic value of circulating markers of neutrophil activation, neutrophil extracellular traps, coagulation and fibrinolysis in patients with terminal cancer
description	Abstract Predicting survival accurately in patients with advanced cancer is important in guiding interventions and planning future care. Objective tools are therefore needed. Blood biomarkers are appealing due to their rapid measurement and objective nature. Thrombosis is a common complication in cancer. Recent data indicate that tumor-induced neutrophil extracellular traps (NETs) are pro-thrombotic. We therefore performed a comprehensive investigation of circulating markers of neutrophil activation, NET formation, coagulation and fibrinolysis in 106 patients with terminal cancer. We found that neutrophil activation and NET markers were prognostic in terminal cancer patients. Interestingly, markers of coagulation and fibrinolysis did not have a prognostic value in this patient group, and there were weak or no correlations between these markers and markers of neutrophil activation and NETs. This suggest that NETs are linked to a poor prognosis through pathways independent of coagulation. Additional studies are needed to determine the utility of circulating neutrophil activation and NET markers, alone or in concert with established clinical parameters, as objective and reliable prognostic tools in advanced cancer.
format	article
author	Axel Rosell Katherina Aguilera Yohei Hisada Clare Schmedes Nigel Mackman Håkan Wallén Staffan Lundström Charlotte Thålin
author_facet	Axel Rosell Katherina Aguilera Yohei Hisada Clare Schmedes Nigel Mackman Håkan Wallén Staffan Lundström Charlotte Thålin
author_sort	Axel Rosell
title	Prognostic value of circulating markers of neutrophil activation, neutrophil extracellular traps, coagulation and fibrinolysis in patients with terminal cancer
title_short	Prognostic value of circulating markers of neutrophil activation, neutrophil extracellular traps, coagulation and fibrinolysis in patients with terminal cancer
title_full	Prognostic value of circulating markers of neutrophil activation, neutrophil extracellular traps, coagulation and fibrinolysis in patients with terminal cancer
title_fullStr	Prognostic value of circulating markers of neutrophil activation, neutrophil extracellular traps, coagulation and fibrinolysis in patients with terminal cancer
title_full_unstemmed	Prognostic value of circulating markers of neutrophil activation, neutrophil extracellular traps, coagulation and fibrinolysis in patients with terminal cancer
title_sort	prognostic value of circulating markers of neutrophil activation, neutrophil extracellular traps, coagulation and fibrinolysis in patients with terminal cancer
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/6878c987d3634635982d478f171288b0
work_keys_str_mv	AT axelrosell prognosticvalueofcirculatingmarkersofneutrophilactivationneutrophilextracellulartrapscoagulationandfibrinolysisinpatientswithterminalcancer AT katherinaaguilera prognosticvalueofcirculatingmarkersofneutrophilactivationneutrophilextracellulartrapscoagulationandfibrinolysisinpatientswithterminalcancer AT yoheihisada prognosticvalueofcirculatingmarkersofneutrophilactivationneutrophilextracellulartrapscoagulationandfibrinolysisinpatientswithterminalcancer AT clareschmedes prognosticvalueofcirculatingmarkersofneutrophilactivationneutrophilextracellulartrapscoagulationandfibrinolysisinpatientswithterminalcancer AT nigelmackman prognosticvalueofcirculatingmarkersofneutrophilactivationneutrophilextracellulartrapscoagulationandfibrinolysisinpatientswithterminalcancer AT hakanwallen prognosticvalueofcirculatingmarkersofneutrophilactivationneutrophilextracellulartrapscoagulationandfibrinolysisinpatientswithterminalcancer AT staffanlundstrom prognosticvalueofcirculatingmarkersofneutrophilactivationneutrophilextracellulartrapscoagulationandfibrinolysisinpatientswithterminalcancer AT charlottethalin prognosticvalueofcirculatingmarkersofneutrophilactivationneutrophilextracellulartrapscoagulationandfibrinolysisinpatientswithterminalcancer
_version_	1718385513168109568

Prognostic value of circulating markers of neutrophil activation, neutrophil extracellular traps, coagulation and fibrinolysis in patients with terminal cancer

Ejemplares similares